Paolo Tarantino: Phase 1 trial of the MMAF-based, HER2-targeting ADC FS-1502 published in Nature Communications
Paolo Tarantino shared on X/Twitter:
“Phase 1 trial of the MMAF-based, HER2-targeting ADC FS-1502 published in Nature Communications. Among 67 patients with HER2+ MBC receiving the 2.3 mg/kg dose, ORR was 53.7%, mPFS 15.5 months. Main adverse effects: liver toxicity, keratitis, hypokalemia. Phase 3 trial ongoing vs. T-DM1.”
Source: Paolo Tarantino/X
Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer.
Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023